Vardenafil
- Generic Name
- Vardenafil
- Brand Names
- Levitra, Staxyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N6O4S
- CAS Number
- 224785-90-4
- Unique Ingredient Identifier
- UCE6F4125H
- Background
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction. During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing ...
- Indication
Vardenafil is indicated for the treatment of erectile dysfunction.
- Associated Conditions
- Erectile Dysfunction
- Associated Therapies
- -
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT00853840
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- China Rehabilitation Research Center
- Target Recruit Count
- 350
- Registration Number
- NCT00725790
- Locations
- 🇨🇳
Beijing Boai Hospital Affiliated to China Rehabilitation Research Center, Beijing, Beijing, China
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 60
- Registration Number
- NCT00718952
- Locations
- 🇨🇳
Peking Union Hospital, Peking Union Medical College, Beijing, Beijing, China
🇨🇳Beijing Shijitan Hospital, Peking University, Beijing, Beijing, China
🇨🇳The General Hospital of Shenyang Military Command, Shenyang, Liaoning, China
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2008-06-26
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00705588
- Locations
- 🇮🇱
Pulmonary Institute, Rabin Medical Center, Petach Tikva, Israel
Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i
- Conditions
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 46
- Registration Number
- NCT00498680
- Locations
- 🇮🇱
Neuro-urology unit, Rambam Medical Center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.